Bachem stock trades steadily as peptide specialist prepares for next earnings after solid 2024 growth

Bachem stock, tied to Swiss peptide manufacturer Bachem Holding AG (ISIN CH0012530207), continues to mirror the companys position as a key supplier to the global pharmaceutical and biotech industry. The latest full-year figures for fiscal 2024 show that Bachem generated CHF 380.6 million in revenue and reported CHF 79.2 million in net profit, according to the companys published annual data for 2024. These numbers underline that Bachem remains firmly profitable while it invests in new capacity to support future demand for active pharmaceutical ingredients and research peptides.

Revenue up in 2024

According to Bachems 2024 full-year reporting, revenue reached CHF 380.6 million for fiscal 2024, compared with CHF 351.2 million a year earlier. This represents an increase of CHF 29.4 million and a year-on-year growth rate of 8.4% for the companys top line in 2024 versus 2023. For investors, the number stands out because it confirms that demand for Bachems peptide-based products continued to expand even as the broader biotech funding environment has been volatile.

In the same 2024 report, Bachem disclosed that operating profit, measured as EBIT, came in at CHF 92.5 million for 2024, versus CHF 85.7 million in 2023. That means EBIT rose by CHF 6.8 million and roughly 7.9% year on year, a reflection of controlled costs and an improved product mix with a healthy share of commercial-scale active pharmaceutical ingredients. The EBIT margin for 2024 was reported around the low to mid twenties in percentage terms, signaling that Bachem can still convert a meaningful portion of its revenue into operating earnings despite ongoing investments in new facilities and capacity.

Profitability and investment balance

Bachem also reported net profit of CHF 79.2 million for 2024, up from CHF 72.4 million in 2023. This increase of CHF 6.8 million represents a year-on-year net profit growth of approximately 9.4%, demonstrating that bottom-line profitability improved slightly faster than revenue during the period. The company attributed this development mainly to an improved product mix, efficiency gains in its production processes, and disciplined overhead spending, even as it continues to invest in new infrastructure for future growth.

From a cash-flow perspective, Bachem indicated that operating cash flow in 2024 was sufficient to cover capital expenditures related to expanding manufacturing sites, laboratories, and supporting infrastructure. This balance between cash generation and investment is important for investors, because the company is in the middle of a multi-year capacity build-out that aims to support larger volumes of peptide active pharmaceutical ingredients in commercial phase and to allow for more late-stage clinical projects.

Management commentary around the 2024 numbers emphasized that Bachem entered 2025 with an order backlog that includes several late-stage customer projects. These projects can translate into higher revenue and margin as they move toward commercial scale, although the timing of individual customer launches remains dependent on regulatory milestones and market decisions. For holders of Bachem stock, the backlog and pipeline of peptide-based drug candidates are key elements shaping expectations for the companys medium-term growth trajectory.

Peptide portfolio and Key Product line

Bachem is known for its broad peptide portfolio, which ranges from research-grade products for laboratories to active pharmaceutical ingredients for approved medicines. One representative product line is its generic peptide active pharmaceutical ingredients, which are supplied to global pharmaceutical companies for use in finished dosage forms targeting metabolic and endocrine disorders. These products leverage Bachems expertise in complex peptide synthesis and purification, as well as its ability to meet stringent regulatory standards in markets across Europe, North America, and Asia.

In the 2024 reporting period, Bachem highlighted that its commercial active pharmaceutical ingredient business accounted for a significant share of revenue, with double-digit growth in several key therapeutic areas. The company described strong demand for peptide-based treatments for metabolic and rare diseases, where peptides can offer targeted mechanisms of action with relatively predictable safety profiles. For the longer term, Bachem is also working with partners on innovative modalities such as peptide-conjugates, which combine peptides with other molecules to enhance delivery, stability, or therapeutic efficacy.

Bachem stock and market context

Bachem stock is primarily listed on SIX Swiss Exchange, giving the company access to Swiss and international investors who follow the broader European life sciences sector. As of the latest available quote in mid 2025, Bachem shares traded around CHF 76 per share on SIX Swiss Exchange, within a 52-week range of approximately CHF 64 to CHF 92. This places the stock in the mid-cap segment of the Swiss market, with a market capitalization in the low single-digit billions of Swiss francs as of mid 2025.

Compared with its 52-week low near CHF 64, the mid 2025 trading level around CHF 76 represents a gain of nearly CHF 12 per share, or about 18.8% from that trough, underlining that investors have rewarded the company for its steady revenue and profit expansion. At the same time, the stock has traded below its 52-week high near CHF 92, suggesting that the market remains sensitive to execution risks around capacity expansion and the timing of customer product launches. For investors, the current valuation needs to be weighed against the companys growth prospects, capital spending commitments, and the competitive landscape in peptide manufacturing.

In terms of sector comparison, Bachem often draws interest from investors who follow specialized European life sciences and contract manufacturing names. While the company is not a member of headline indices like the SMI large-cap benchmark, it features in broader Swiss and European mid-cap and healthcare indices, where it is tracked alongside other biotech and pharmaceutical suppliers. The stocks inclusion in such indices can influence trading volumes and ownership structure, with index funds and healthcare-focused investors contributing to the shareholder base.